Lantheus Holdings, Inc. — 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing; the supplied text does not provide a clear standalone fourth-quarter income statement. Lantheus develops, manufactures and commercializes diagnostic imaging, radiotherapeutic and AI products. It reported one operating segment in 2021.
Financial performance
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Revenue | $425.2 million | $339.4 million | +25.3% |
| Gross profit | $187.7 million | $138.8 million | +35.3% |
| Gross margin | 44.1% | 40.9% | +3.2 percentage points |
| Operating loss | $60.8 million | $4.2 million | Loss widened |
| Net loss | $71.3 million | $13.5 million | Loss widened |
| Operating cash flow | $53.9 million | $16.4 million | +$37.5 million |
| Capital expenditures | $12.1 million | $12.5 million | -$0.3 million |
Revenue growth primarily reflected the June 2021 U.S. launch of PYLARIFY, higher DEFINITY and TechneLite volumes, and a full year of Progenics products versus only a partial year in 2020. PYLARIFY generated $43.4 million in 2021 revenue. DEFINITY revenue was $232.8 million (+18.8%) and TechneLite was $91.3 million (+7.5%). Other precision diagnostics declined 26.8% to $27.0 million.
Operating expenses rose 84.5% to $263.8 million, including a $72.4 million non-cash fair-value expense for contingent assets and liabilities, including Progenics acquisition CVRs. Sales and marketing rose 67.3% to $68.4 million, and R&D rose 37.1% to $45.0 million. A $15.3 million gain on the Puerto Rico subsidiary sale partly offset the operating loss. Interest expense was $7.8 million, down from $9.5 million.
Liquidity, debt and cash flows
- Cash and cash equivalents were $98.5 million at year-end, compared with $79.6 million in 2020; restricted cash was an additional $2.1 million.
- Current assets were $235.8 million and current liabilities $90.5 million. Accounts receivable increased to $89.3 million from $54.0 million.
- Term-loan principal was $175.0 million, of which $11.3 million was due within 12 months; the $200 million revolving facility was undrawn. The company reported compliance with debt covenants.
- Net cash used in financing was $39.3 million, mainly reflecting debt repayments, including repayment of the $30.9 million Royalty-Backed Loan in March 2021.
- Management said cash, operating cash generation and continued access to the revolver should meet requirements over the next 12 months and beyond. This assessment depends on operating performance and covenant capacity.
Material developments, outlook and risks
- PYLARIFY launch: FDA approval came in May 2021 and U.S. commercial launch began in June. The product was broadly available nationwide by year-end; 21 PET manufacturing facilities were qualified during 2021. Its Medicare outpatient transitional pass-through status began January 1, 2022 and is expected to end December 31, 2024. The filing gives no specific revenue or earnings guidance.
- DEFINITY and manufacturing: DEFINITY remained the largest product, with estimated U.S. ultrasound-enhancing-agent share above 80%. DEFINITY RT and VIALMIX RFID became commercially available in Q4 2021. After year-end, the FDA approved commercial DEFINITY manufacturing at Lantheus’s North Billerica facility, with product available from that facility beginning February 23, 2022.
- COVID-19: Hospital staffing and access constraints affected DEFINITY and AZEDRA; Xenon procedure volumes remained reduced. Management cautioned that impacts could continue, with duration and magnitude uncertain.
- Supply and competition: Mo-99 supply remains exposed to supplier and reactor interruptions. The NTP agreement was due to expire March 31, 2022, and an extension was being negotiated. The company also depends on third parties for several products and components. PYLARIFY faces current and prospective PSMA imaging competition.
- Reimbursement and regulation: Management flagged uncertainty over PYLARIFY payment after pass-through status ends, and potential FDA reclassification of imaging agents from drugs to devices. DEFINITY may face generic challenges despite later-expiring patents.
- Pipeline: The 1095 Phase 2 ARROW study continued after an interim review, with enrollment completion expected later in 2022. LMI 1195 was in Phase 3. These are expectations, not guarantees; development and commercialization outcomes remain uncertain.
- CVRs and unusual items: CVRs entitle holders to 40% of PYLARIFY U.S. net sales above specified 2022 and 2023 thresholds, subject to an aggregate cap. Their fair value rose to $73.2 million at year-end as part of total contingent consideration liabilities of $86.2 million. On January 31, 2022, Lantheus reached a Novartis settlement expected to provide a $24.0 million lump-sum payment plus certain fee and expense reimbursements.
- Other obligations: Potential contingent payments include up to approximately $100 million under the CVRs, $85 million related to a prior Progenics acquisition, and $170.5 million under license agreements; timing and amounts are uncertain. Asset retirement obligations were $20.8 million, following a $5.3 million non-cash increase from a revised useful-life estimate.
The filing provides no clear quantitative earnings or revenue forecast. Management described growth opportunities in PYLARIFY and DEFINITY, while emphasizing launch execution, reimbursement, supply, pandemic and competitive uncertainties.
Most important facts for investors to verify
- PYLARIFY adoption, revenue trajectory, manufacturing-site approvals and customer access; also assess the CVR payment thresholds and likely cash impact.
- Whether the NTP Mo-99 supply agreement was extended and whether supply reliability or alternative sources improved.
- DEFINITY contribution and the new in-house facility’s production, cost and supply benefits; monitor generic challenges and competitor pressure.
- PYLARIFY reimbursement after the expected December 2024 end of transitional pass-through status, and any FDA action on imaging-agent classification.
- Cash generation, receivable collections, debt service and covenant headroom, alongside contingent liabilities and pipeline spending.